SCHEMBL13329344

SCHEMBL13329344

Cc1nc2c(c(=O)n1C(c1ccccc1)c1ccccc1)CN(CC1CCC(C(F)(F)F)CC1)CC2

nearest known ligand 0.36

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ CLPP Q16740 3/20 0.36
▸ CYP1A2 P05177 1/20 0.35
▸ GAA P10253 1/20 0.35
▸ CYP2C9 P11712 1/20 0.35
▸ ADORA2A P29274 1/20 0.35
▸ GABRA1 P14867 2/20 0.35
▸ GABRA5 P31644 2/20 0.35
▸ GABRA3 P34903 2/20 0.35
▸ GABRA2 P47869 2/20 0.35
▸ CNR2 P34972 2/20 0.34
▸ RBP4 P02753 2/20 0.34
▸ CFTR P13569 1/20 0.34
▸ OPRM1 P35372 1/20 0.33
▸ OPRD1 P41143 1/20 0.33
▸ DRD2 P14416 1/20 0.33
▸ GNRHR P30968 2/20 0.33
▸ KMT2A Q03164 1/20 0.32
▸ AVPR1A P37288 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13328989 0.88 CLPP (0.46) CLPPCYP1A2GAACYP2C9ADORA2A
SCHEMBL13329345 0.87 CYP1A2 (0.32) CYP1A2GAACYP2C9ADORA2AKMT2A
SCHEMBL13329098 0.84 KMT2A (0.33) KMT2A
SCHEMBL13329327 0.81 KDM4E (0.42) DRD2
SCHEMBL13250523 0.80 KMT2A (0.31) KMT2A
SCHEMBL13328799 0.78 CYP1A2 (0.53) CLPPCYP1A2GAACYP2C9ADORA2A
SCHEMBL13329060 0.78 KDM4E (0.43) CLPPCYP1A2GAACYP2C9ADORA2A
SCHEMBL13328804 0.78 CLPP (0.54) CLPPCYP1A2GAACYP2C9ADORA2A
SCHEMBL29896651 0.78 PRLHR (0.39) —
SCHEMBL29896563 0.78 PRLHR (0.39) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8318751-B2 Pyrimidinone derivatives and methods of use thereof MERCK SHARP & DOHME CORP. (US) 2012-11-27 — — US disclosed
US-8318751-B2 Pyrimidinone derivatives and methods of use thereof MERCK SHARP & DOHME CORP. (US) 2012-11-27 — — US disclosed
US-20100113487-A1 PYRIMIDINONE DERIVATIVES AND METHODS OF USE THEREOF MERCK SHARP & DOHME CORP. 2010-05-06 — — US disclosed
US-20100113487-A1 PYRIMIDINONE DERIVATIVES AND METHODS OF USE THEREOF MERCK SHARP & DOHME CORP. 2010-05-06 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100113487-A1 PYRIMIDINONE DERIVATIVES AND METHODS OF USE THEREOF GPR119, GPR180, GPR17 CLPP 4609/4885CYP1A2 1604/4885GAA 913/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback